PNU-282987 hydrate

• Catalog No.: P6499
• M. F.: C14H20Cl2N2O2
• M. W.: 319.2268
• Purity: ≥98% (HPLC)
• Storage: desiccated

SYNONYMS

• IUPAC name: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide hydrate hydrochloride
• IUPAC Traditional name: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide hydrate hydrochloride
• Synonyms: N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chloro-benzamide monohydrochloride hydrate

DATABASE IDS

• PubChem SID: 24898770

PROPERTIES

• Empirical Formula (Hill Notation): C14H17ClN2O · HCl · xH2O
• Purity: ≥98% (HPLC)
• Apperance: solid
• Solubility: DMSO: >10 mg/mL
• Storage Condition: desiccated
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (简体中文)

Caution
Air sensitive
Biochem/physiol Actions
Decreased expression of a homomeric alpha7 nicotinic acetylcholine receptor (nAChR) is connected with inability to process sensory information in schizophrenia. PNU-282987 is a novel selective agonist of the alpha7 nAChR that evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity. The alpha7 nAChR agonist PNU-282987 improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia.

Description (English)

Caution
Air sensitive
Biochem/physiol Actions
Decreased expression of a homomeric alpha7 nicotinic acetylcholine receptor (nAChR) is connected with inability to process sensory information in schizophrenia. PNU-282987 is a novel selective agonist of the alpha7 nAChR that evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity. The alpha7 nAChR agonist PNU-282987 improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia.